Unknown PHASE3 INTERVENTIONAL 1-arm NCT02761460

The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia

The Study of Evaluating the Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia

Sponsor: wang shusen

Interventions PEG-rhG-CSF

Updated 7 times since 2017 Last updated: May 30, 2017 Started: May 4, 2016 Primary completion: Apr 30, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02761460, this PHASE3 trial focuses on Breast Cancer and remains ongoing. Sponsored by wang shusen, it has been updated 7 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2019 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jun 2018 — Jun 2019 [monthly]

Recruiting PHASE3

▶ Show 2 earlier versions

Jun 2017 — Jun 2018 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jan 2017 — Jun 2017 [monthly]

Not Yet Recruiting PHASE3

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

wang shusen

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China